par Salgado, Roberto;Denkert, Carsten;Demaria, S;Sirtaine, N.;Klauschen, F;Pruneri, Giancarlo;Wienert, S;Van den Eynden, Gert;Baehner, Frederick L;Pénault-Llorca, Frederique;Perez, E A;Thompson, E A;Symmans, W Fraser;Richardson, A L;Brock, John;Criscitiello, Carmen ;Bailey, H;Ignatiadis, Michail ;Floris, Giuseppe;Sparano, Joseph A;Kos, Z;Nielsen, T;Rimm, David D.L.;Allison, K H;Reis-Filho, Jorge Sergio;Loibl, Sibylle;Sotiriou, Christos ;Viale, G;Badve, S;Adams, S.;Willard-Gallo, Karen ;Loi, Sherene
Référence Annals of oncology
Publication Publié, 2014-09
Référence Annals of oncology
Publication Publié, 2014-09
Article révisé par les pairs
Résumé : | The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. |